Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
He M, Jiang YZ, Gong Y, Fan L, Liu XY, Liu Y, Tang LC, Mo M, Hou YF, Di GH, Liu GY, Yu KD, Wu J, Yan X, Zeng XH, Fu DY, Song CG, Zhuang ZG, Wu KJ, Wang J, Wang ZH, Shao ZM.
He M, et al. Among authors: liu xy, liu y, liu gy.
BMJ. 2024 Oct 23;387:e079603. doi: 10.1136/bmj-2024-079603.
BMJ. 2024.
PMID: 39442958
Free PMC article.
Clinical Trial.